Many tumors express increased CD46 levels on their surface, and anti-tumor activity of Edmonston MeV has been shown in several mouse xenograft models for lymphoma, multiple myeloma, glioma, ovarian, colorectal, breast, and liver cancers [176,185,186,187,188,189,190,191]. This evidence concerns the gene CD46 and neoplasm.